Burlington Stores Inc vs Heron Therapeutics Inc — how do they compare? Burlington Stores Inc trades at $343.28 (market cap $21.04B), while Heron Therapeutics Inc trades at $0.42 (market cap $82.52M). The key difference: Burlington Stores Inc is far larger — about 255× Heron Therapeutics Inc's market cap, and Burlington Stores Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| BURL | HRTX | |
|---|---|---|
Market Cap | $21.04B | $82.52M |
Sector | Consumer Cyclical | Health |
52-Week High | $347.82 | $2.04 |
52-Week Low | $242.43 | $0.39 |
Enterprise Value | $26.17B | $180.42M |
Signals from Pluang's Aura AI — not financial advice
Burlington Stores (BURL) trades at $327.59, showing minimal daily movement with a slight 0.04% decline. The stock maintains strong bullish technical signals with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. Fundamentally, the company demonstrates robust performance with consistent earnings beats, including Q1 2026 EPS of $2.01 exceeding expectations of $1.80. Revenue growth continues with 2025 reaching $10.63 billion and projected increase to $11.9 billion in 2026.
Outlook remains positive with 94% analyst buy ratings and $364.40 consensus price target representing 11% upside. Key opportunities include margin expansion and store productivity improvements, while risks involve competitive retail pressures and inventory management challenges. The company's strong cash flow generation and debt-to-asset ratio of 19.5% provide financial stability for continued growth initiatives.
HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.
While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.
Trailing returns across standard periods
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →